RBC analyst Randall Stanicky reiterated an Outperform rating and $194 price target on Jazz Pharmaceuticals after hosting a dinner with Chairman and CEO Bruce Cozadd. In a research note to investors, Stanicky said he left the dinner more confident in targeted business development with a view that a deal is likely in 2018. Overall, the analyst said Jazz remains a top pick and sees “lots” of room to run for the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.